CO5271726A1 - Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma - Google Patents

Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma

Info

Publication number
CO5271726A1
CO5271726A1 CO99054477A CO99054477A CO5271726A1 CO 5271726 A1 CO5271726 A1 CO 5271726A1 CO 99054477 A CO99054477 A CO 99054477A CO 99054477 A CO99054477 A CO 99054477A CO 5271726 A1 CO5271726 A1 CO 5271726A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
ionic complex
water
same
polypeptide
Prior art date
Application number
CO99054477A
Other languages
English (en)
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5271726A1 publication Critical patent/CO5271726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica acuosa que contiene un polipéptido farmacéuticamente efectivo seleccionado del grupo consistente en proteínas de erizo, proteínas morfogenéticas de hueso, factores de crecimiento, eritropoyetina, trombopoyetina, factor estimulante de la colonia de granulocitos, interleucinas e interferones, caracterizado porque dicha composición contiene, adicionalmente, un compuesto anfifílico como sustancia auxiliar, formando dicho polipéptido y dicho compuesto anfifílico un complejo iónico, de modo que la formación del complejo no aumenta la solubilidad de dicho polipéptido.
CO99054477A 1998-09-01 1999-08-27 Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma CO5271726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116494 1998-09-01

Publications (1)

Publication Number Publication Date
CO5271726A1 true CO5271726A1 (es) 2003-04-30

Family

ID=8232558

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99054477A CO5271726A1 (es) 1998-09-01 1999-08-27 Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma

Country Status (30)

Country Link
US (3) US6867182B2 (es)
EP (1) EP1002547B1 (es)
JP (1) JP3664373B2 (es)
KR (1) KR100403075B1 (es)
CN (1) CN1325118C (es)
AR (1) AR023044A1 (es)
AT (1) ATE318616T1 (es)
AU (1) AU755930B2 (es)
BR (1) BR9903984B1 (es)
CA (1) CA2281049C (es)
CO (1) CO5271726A1 (es)
DE (1) DE69930033T2 (es)
ES (1) ES2258830T3 (es)
GC (1) GC0000107A (es)
HR (1) HRP990272B1 (es)
HU (1) HUP9902952A1 (es)
ID (1) ID22964A (es)
IL (1) IL131626A0 (es)
MA (1) MA26682A1 (es)
MY (1) MY127935A (es)
NO (1) NO994214L (es)
NZ (1) NZ337527A (es)
PE (1) PE20001027A1 (es)
PL (1) PL194218B1 (es)
RU (1) RU2180855C2 (es)
SG (1) SG85670A1 (es)
TR (1) TR199902103A2 (es)
TW (1) TW570805B (es)
YU (1) YU42399A (es)
ZA (1) ZA995601B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
KR100610003B1 (ko) * 2003-06-10 2006-08-08 주식회사 엘지생명과학 혈청 알부민을 함유하지 않는 안정한 인 에리쓰로포이에틴용액 제형
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
DK2422789T3 (en) * 2004-05-19 2018-02-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct INJECTABLE COMPOSITION CONTAINING SODIUM DEOXYCHOLATE
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
EP1905433A1 (en) * 2005-07-15 2008-04-02 Transcu Ltd. Percutaneous absorption patch with application position indicating function, and iontophoresis device
JP2007037868A (ja) * 2005-08-05 2007-02-15 Transcutaneous Technologies Inc 経皮投与装置及びその制御方法
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
AU2006289888B2 (en) * 2005-09-16 2010-12-02 Tti Ellebeau, Inc. Catheter type iontophoresis apparatus
CN101277737A (zh) * 2005-09-30 2008-10-01 Tti优而美株式会社 将多种活性剂输送至生物界面的离子电渗装置
US20080033338A1 (en) * 2005-12-28 2008-02-07 Smith Gregory A Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
US7848801B2 (en) * 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2007123707A1 (en) * 2006-03-30 2007-11-01 Tti Ellebeau, Inc. Controlled release membrane and methods of use
KR20090027755A (ko) * 2006-07-05 2009-03-17 티티아이 엘뷰 가부시키가이샤 자기-조립형 수지상 중합체를 함유하는 전달 장치 및 이의 사용 방법
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
FR2908414B1 (fr) * 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
WO2008087803A1 (ja) * 2007-01-16 2008-07-24 Hokkaido University 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5675347B2 (ja) * 2007-06-01 2015-02-25 ノボ・ノルデイスク・エー／エス 安定した非水性薬学的組成物
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
RU2011113755A (ru) * 2008-09-10 2012-10-20 Транску Лтд. (Sg) Устройство и способ для распределения вязких жидкостей на основе hpc в пористые субстраты, например, непрерывным ленточным способом
WO2012134540A2 (en) * 2010-10-22 2012-10-04 Vanderbilt University Injectable synthetic pur composite
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP6007105B2 (ja) * 2009-12-22 2016-10-12 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
AU2013235336B2 (en) 2012-03-23 2016-09-08 Amicrobe, Inc. Compositions and uses of antimicrobial materials with tissue-compatible properties
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
EP3372247B1 (en) * 2015-11-04 2022-01-05 Postech Academy-Industry Foundation Composition for skin permeation comprising cationic molecular transporter and protein
BR112019011761A2 (pt) 2016-12-16 2019-11-05 Novo Nordisk As composições farmacêuticas contendo insulina
CA3058901A1 (en) 2017-04-06 2018-10-11 Amicrobe, Inc. Compositions and uses of locally applied antimicrobials with enhanced performance and safety
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
MX2021012032A (es) * 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61500790A (ja) 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
LU85971A1 (fr) 1985-06-25 1987-01-13 Oreal Nouveaux composes lipidiques amphiphiles, leur procede de preparation et leurs applications,notamnent en cosmetique et en dermopharmacie
JPS62207226A (ja) 1986-03-07 1987-09-11 Sumitomo Pharmaceut Co Ltd 経鼻投与用製剤
FR2615194B1 (fr) 1987-05-11 1991-06-14 Rhone Poulenc Chimie Particules de polymere comportant, implantees a leur surface des molecules amphiphiles portant des groupes ionogenes ou reactifs, leur procede de preparation et leur application en biologie
DE68927479T2 (de) 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
FR2694559B1 (fr) 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP3290745B2 (ja) 1993-03-31 2002-06-10 藤平 正道 単分子膜のパターン形成方法
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
FR2714621B1 (fr) 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5853741A (en) * 1996-06-28 1998-12-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Vitamin C delivery system
WO1998030576A1 (en) * 1996-10-07 1998-07-16 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
RU2179981C2 (ru) 1996-10-15 2002-02-27 Сейкагаку Корпорейшн Соли переходного металла с полипептидом и способ повышения активности полипептида против вич
WO1998020298A1 (en) * 1996-11-08 1998-05-14 Northern Magnetics, Inc. Sensing and controlling the location of elements of a linear motor
US5759811A (en) * 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
DE59804785D1 (de) 1997-11-22 2002-08-22 Roche Diagnostics Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
EP0919618A1 (de) 1997-11-28 1999-06-02 Boehringer Mannheim Gmbh Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
ATE295372T1 (de) 1997-12-03 2005-05-15 Biogen Inc Hydrophobisch-modifizierte hedgehog protein zusammensetzungen und verfahren
JP3648051B2 (ja) * 1998-02-02 2005-05-18 富士通株式会社 関連情報検索装置及びプログラム記録媒体
EP0947201B1 (en) * 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
CA2260423C (en) 1998-02-04 2006-06-20 Kurt Lang Pharmaceutical composition of hedgehog proteins and use thereof
EP0953576B1 (en) * 1998-04-30 2005-11-02 Curis, Inc. Active hedgehog protein conjugate, process for its production and use
US20050021440A1 (en) * 2003-04-04 2005-01-27 Scott Dresden Integrated dynamic pricing and procurement support for e-commerce advertising channels
US20070203906A1 (en) * 2003-09-22 2007-08-30 Cone Julian M Enhanced Search Engine
US20050114319A1 (en) * 2003-11-21 2005-05-26 Microsoft Corporation System and method for checking a content site for efficacy
US10515374B2 (en) * 2005-03-10 2019-12-24 Adobe Inc. Keyword generation method and apparatus

Also Published As

Publication number Publication date
KR20000022777A (ko) 2000-04-25
HUP9902952A1 (hu) 2000-06-28
CA2281049A1 (en) 2000-03-01
MY127935A (en) 2007-01-31
NO994214D0 (no) 1999-08-31
AU4486699A (en) 2000-03-16
EP1002547B1 (en) 2006-03-01
YU42399A (sh) 2001-05-28
JP3664373B2 (ja) 2005-06-22
JP2000086532A (ja) 2000-03-28
ID22964A (id) 1999-12-23
US8519098B2 (en) 2013-08-27
IL131626A0 (en) 2001-01-28
TW570805B (en) 2004-01-11
PL335203A1 (en) 2000-03-13
HRP990272A2 (en) 2000-06-30
GC0000107A (en) 2005-06-29
NZ337527A (en) 2000-12-22
DE69930033T2 (de) 2006-10-12
US20050123610A1 (en) 2005-06-09
ZA995601B (en) 2000-09-27
CN1250669A (zh) 2000-04-19
RU2180855C2 (ru) 2002-03-27
DE69930033D1 (de) 2006-04-27
HU9902952D0 (en) 1999-10-28
SG85670A1 (en) 2002-01-15
PE20001027A1 (es) 2000-10-13
EP1002547A1 (en) 2000-05-24
US6867182B2 (en) 2005-03-15
CA2281049C (en) 2010-11-02
CN1325118C (zh) 2007-07-11
HRP990272B1 (en) 2006-11-30
PL194218B1 (pl) 2007-05-31
ES2258830T3 (es) 2006-09-01
AU755930B2 (en) 2003-01-02
US20020028766A1 (en) 2002-03-07
TR199902103A2 (xx) 2000-04-21
BR9903984A (pt) 2001-03-13
KR100403075B1 (ko) 2003-10-30
NO994214L (no) 2000-03-02
BR9903984B1 (pt) 2011-04-19
AR023044A1 (es) 2002-09-04
ATE318616T1 (de) 2006-03-15
US20080064854A1 (en) 2008-03-13
MA26682A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
CO5271726A1 (es) Composicion farmaceutica soluble en agua en un complejo ionico y el uso de la misma
IT8220781A0 (it) Bifosfonati farmacologicamente attivi, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1199962B (it) Ciclosporine,processi per la loro preparazione,uso farmaceutico delle stesse e composizioni farmaceutiche che le contengono
ATE251448T1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
SE8602723L (sv) Tiazoler, deras framstellning och farmaceutiska kompositioner innehallande dem
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
FR2681067B1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
ES2193246T3 (es) Cefalosporinas antibacterianas.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
IT1206505B (it) Nuovi derivati benzotiazepinonici, metodo per la loro preparazione e composizioni farmaceutiche che licontengono.
ES2043957T3 (es) Composicion obtenida a partir de cortezas de arroz y procedimiento para su preparacion.
FR2663326B2 (fr) Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
FR2776291B1 (fr) Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
IT8323058A0 (it) Derivati di 2,5-piperazindione biologicamente attivi, processi per la loro preparazione e composizioni farmaceutiche che licontengono.
IT8323059A0 (it) Tripeptide e tetrapeptide alchilamidi biologicamente attive, processi per la loro preparazione e composizioni farmaceutiche che le contengono.
ITMI912745A1 (it) Derivati 5h-benzodiazepinici, composizioni farmaceutiche che li contengono e procedimento per la loro preparazione.
SE8302979D0 (sv) Piperazine derivatives, their production and pharmaceutical compositions containing them
EA199900750A1 (ru) Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
IT1201523B (it) Eterociclilfenilfomramidine,processi per la loro preparazione e loro uso farmaceutico
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
ECSP993119A (es) Composicion farmaceutica soluble en agua que contiene un complejo ionico y su uso
IT8220356A0 (it) Guanidino eterociclifenilamidine, processi per la loro preparazione e loro impiego farmaceutico.
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof

Legal Events

Date Code Title Description
FC Application refused